protoporphyrin ix has been researched along with Pain in 18 studies
protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685
protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment." | 9.20 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| "To determine the impact of skin pretreatment with microneedles (MNs) on ALA- and MAL-induced protoporphyrin IX (PpIX) production, as well as MN impact on pain sensations during light exposure and erythema after PDT." | 9.14 | Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. ( Donnelly, RF; Garland, MJ; Iani, V; Juzeniene, A; Mikolajewska, P; Moan, J; Morrow, DI; Singh, TR, 2010) |
| "We assessed whether PDT clinical outcome and pain during treatment were correlated with protoporphyrin IX fluorescence intensity and photobleaching." | 7.79 | Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy. ( Barge, J; Kasraee, B; Piffaretti, F; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2013) |
| "In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain." | 7.74 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "To compare pain during PDT using two different fluence rates, and also to evaluate the association between pain and protoporphyrin IX (PpIX) fluorescence, lesion type, lesion preparation and lesion localization." | 7.74 | Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. ( Philipsen, PA; Skiveren, J; Wiegell, SR; Wulf, HC, 2008) |
| "Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment." | 5.20 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| " Objective and visual erythema, protoporphyrin IX (PpIX) fluorescence and pain were evaluated." | 5.19 | Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial. ( Petersen, B; Wiegell, SR; Wulf, HC, 2014) |
| "To determine the impact of skin pretreatment with microneedles (MNs) on ALA- and MAL-induced protoporphyrin IX (PpIX) production, as well as MN impact on pain sensations during light exposure and erythema after PDT." | 5.14 | Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. ( Donnelly, RF; Garland, MJ; Iani, V; Juzeniene, A; Mikolajewska, P; Moan, J; Morrow, DI; Singh, TR, 2010) |
| "To evaluate the efficacy and safety of LPDL alone versus LPDL in photodynamic therapy with methylaminolevulinic acid (MAL-LPDL) for acne vulgaris." | 5.13 | Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial. ( Haedersdal, M; Togsverd-Bo, K; Wiegell, SR; Wulf, HC, 2008) |
| "We assessed whether PDT clinical outcome and pain during treatment were correlated with protoporphyrin IX fluorescence intensity and photobleaching." | 3.79 | Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy. ( Barge, J; Kasraee, B; Piffaretti, F; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2013) |
| "Because of the retrospective study design not all factors that may influence pain (eg, protoporphyrin IX fluorescence) were recorded." | 3.76 | Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. ( Denk, K; Enk, A; Gholam, P; Hartmann, M; Sehr, T, 2010) |
| "In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain." | 3.74 | Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008) |
| "To compare pain during PDT using two different fluence rates, and also to evaluate the association between pain and protoporphyrin IX (PpIX) fluorescence, lesion type, lesion preparation and lesion localization." | 3.74 | Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. ( Philipsen, PA; Skiveren, J; Wiegell, SR; Wulf, HC, 2008) |
| "Pain is the main acute adverse event during photodynamic therapy of skin lesions." | 2.74 | Cold water and pauses in illumination reduces pain during photodynamic therapy: a randomized clinical study. ( Haedersdal, M; Wiegell, SR; Wulf, HC, 2009) |
| "Post-treatment inflammation can often be severe and cause inconvenient down-time for the patients and their employers." | 1.48 | The background and philosophy behind daylight photodynamic therapy. ( Wulf, HC, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wulf, HC | 8 |
| Piffaretti, F | 1 |
| Zellweger, M | 1 |
| Kasraee, B | 1 |
| Barge, J | 1 |
| Salomon, D | 1 |
| van den Bergh, H | 1 |
| Wagnières, G | 1 |
| Wiegell, SR | 6 |
| Petersen, B | 2 |
| Lerche, CM | 1 |
| Fabricius, S | 1 |
| Philipsen, PA | 2 |
| Shen, Y | 1 |
| Zhang, ZJ | 1 |
| Zhu, MD | 1 |
| Jiang, BC | 1 |
| Yang, T | 1 |
| Gao, YJ | 1 |
| Kanick, SC | 1 |
| Davis, SC | 1 |
| Zhao, Y | 1 |
| Sheehan, KL | 1 |
| Hasan, T | 1 |
| Maytin, EV | 1 |
| Pogue, BW | 1 |
| Chapman, MS | 1 |
| Nissen, CV | 1 |
| Heerfordt, IM | 1 |
| Mikkelsen, CS | 1 |
| Gandy, J | 1 |
| Labadie, B | 1 |
| Bierman, D | 1 |
| Zachary, C | 1 |
| Cottrell, WJ | 1 |
| Paquette, AD | 1 |
| Keymel, KR | 1 |
| Foster, TH | 1 |
| Oseroff, AR | 1 |
| Haedersdal, M | 2 |
| Mikolajewska, P | 2 |
| Iani, V | 2 |
| Juzeniene, A | 2 |
| Moan, J | 2 |
| Gholam, P | 1 |
| Denk, K | 1 |
| Sehr, T | 1 |
| Enk, A | 1 |
| Hartmann, M | 1 |
| Donnelly, RF | 1 |
| Garland, MJ | 1 |
| Morrow, DI | 1 |
| Singh, TR | 1 |
| Tyrrell, J | 1 |
| Campbell, SM | 1 |
| Curnow, A | 1 |
| Gaál, M | 1 |
| Kui, R | 1 |
| Hunyadi, Z | 1 |
| Kemény, L | 1 |
| Gyulai, R | 1 |
| Togsverd-Bo, K | 1 |
| Skiveren, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Indoor Daylight Photo Dynamic Therapy (PDT) for Actinic Keratosis[NCT03805737] | 43 participants (Actual) | Interventional | 2019-11-01 | Completed | |||
| Portable Measurement of Protoporphyrin IX in the Skin[NCT04223570] | 218 participants (Anticipated) | Observational | 2022-12-01 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for protoporphyrin ix and Pain
| Article | Year |
|---|---|
[Fluorescence diagnosis of non-melanoma skin cancer].
Topics: Aminolevulinic Acid; Apoptosis; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous | 2012 |
7 trials available for protoporphyrin ix and Pain
| Article | Year |
|---|---|
Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents; C | 2014 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pulse photodynamic therapy reduces inflammation without compromising efficacy in the treatment of multiple mild actinic keratoses of the face and scalp: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Erythema; Facial Dermatoses; Female; Fluorescence; Hum | 2016 |
Increased protoporphyrin IX accumulation does not improve the effect of photodynamic therapy for actinic keratosis: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Curettage; Drug Eruptions; Erythema; Female; Fluoresce | 2017 |
Cold water and pauses in illumination reduces pain during photodynamic therapy: a randomized clinical study.
Topics: Aged; Cold Temperature; Female; Fluorescence; Humans; Keratosis, Actinic; Male; Middle Aged; Pain; P | 2009 |
Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema.
Topics: Administration, Cutaneous; Adult; Aminolevulinic Acid; Erythema; Female; Humans; Light; Male; Needle | 2010 |
Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial.
Topics: Acne Vulgaris; Adult; Aminolevulinic Acid; Edema; Erythema; Female; Fluorescence; Humans; Laser Ther | 2008 |
10 other studies available for protoporphyrin ix and Pain
| Article | Year |
|---|---|
The background and philosophy behind daylight photodynamic therapy.
Topics: Apoptosis; Humans; Inflammation; Light; Pain; Photochemotherapy; Photosensitizing Agents; Protoporph | 2018 |
Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy.
Topics: Aged; Aminolevulinic Acid; Fluorescence; Humans; Keratosis, Actinic; Middle Aged; Pain; Pain Measure | 2013 |
Correlation between treatment time, photobleaching, inflammation and pain after photodynamic therapy with methyl aminolevulinate on tape-stripped skin in healthy volunteers.
Topics: Adult; Aminolevulinic Acid; Erythema; Fluorescence; Forearm; Humans; Inflammation; Male; Middle Aged | 2015 |
Exogenous induction of HO-1 alleviates vincristine-induced neuropathic pain by reducing spinal glial activation in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Disease Models, | 2015 |
Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time.
Topics: Aminolevulinic Acid; Face; Humans; Keratosis, Actinic; Male; Middle Aged; Pain; Photochemotherapy; P | 2017 |
Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Huma | 2008 |
Topical aminolaevulinic acid- and aminolaevulinic acid methyl ester-based photodynamic therapy with red and violet light: influence of wavelength on pain and erythema.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Animals; Erythema; Humans; Lasers; Mice; Mice, | 2009 |
Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cosmetic Techniques; Female; Humans; Keratosis, | 2010 |
The effect of air cooling pain relief on protoporphyrin IX photobleaching and clinical efficacy during dermatological photodynamic therapy.
Topics: Aged; Air; Air Conditioning; Cold Temperature; Female; Humans; Light; Male; Oxygen; Pain; Pain Manag | 2011 |
Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate.
Topics: Acne Vulgaris; Adult; Aged; Female; Humans; Keratosis; Male; Pain; Pain Measurement; Photochemothera | 2008 |